迪哲医药(688192) - 2025 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of 801.14 million yuan in 2025, representing a 122.60% increase compared to the previous year[3] - The net loss attributable to the parent company was 763.31 million yuan, a reduction of 82.65 million yuan from the previous year's loss[7] - The company's total assets increased by 74.69% to 3.00 billion yuan, while equity attributable to the parent company surged by 568.16% to 1.29 billion yuan[3] - The weighted average return on net assets improved to -73.92%, up from -161.12% in the previous year, indicating a positive trend in financial performance[3] Research and Development - Research and development expenses for the year amounted to 855.61 million yuan, reflecting the company's commitment to innovation[8] - The company is actively expanding the application potential of its commercialized products, with ongoing clinical trials for Shuwozhe® and Gaoruizhe® in NSCLC[12] Product Development and Approval - The company successfully launched two products, Shuwozhe® and Gaoruizhe®, which were included in the national medical insurance directory, significantly enhancing patient accessibility[6] - Shuwozhe® received FDA approval for treating adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, marking a significant milestone in the company's product portfolio[9] - The company’s subsidiary obtained a drug production license, ensuring qualifications for future commercial production[12] Capital and Liquidity - The company raised 1.773 billion yuan through a private placement of shares, significantly boosting its liquidity and capital reserves[7]